Cline Christopher R.'s Form 4 filing
Travere Therapeutics, Inc. (TVTX) · filed Apr 15, 2026
- Accession no.
- 0001943192-26-000003
- Filed
- Apr 15, 2026
- Trade date
- Apr 13-15, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market sales total $349.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cline Christopher R.CIK 0001943192 | Officer (CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Common Stock | AGrant or awardAcquired | +14,000 | $0.00 | $0 | 125,226 | Direct | |
| Apr 13, 2026 | Common Stock | SSaleDisposed | −65 | $28.85 | −$1,875.25 | 125,161 | Direct | |
| Apr 14, 2026 | Common Stock | SSaleDisposed | −9 | $41.07 | −$369.63 | 125,152 | Direct | |
| Apr 14, 2026 | Common Stock | SSaleDisposed | −7,239 | $41.93 | −$303,531.27 | 117,913 | Direct | |
| Apr 15, 2026 | Common Stock | SSaleDisposed | −1,014 | $42.61 | −$43,206.54 | 116,899 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.